リンパ球系細胞由来の悪性腫瘍で皮膚以外の臓器に腫瘍細胞を認めないものを原発性皮膚リンパ腫といい,その90%がT細胞由来の皮膚T細胞リンパ(cutaneous T cell lymphoma:CTCL)である.菌状息肉症(mycosis fungoides:MF)Sezary症候群がCTCLの代表疾患である.MFは経過により紅斑期,局面期,腫瘍期に分類される.Sezary症候群は強い掻痒を伴う,紅皮症,表在リンパ節腫脹,末梢血中での異常リンパ球出現の3主徴を特徴とする.
最新の治療状況
MF,Sezary症候群ともに治療は同じで,①ステロイド外用,②psoralen ultra violet A(PUVA),中波長紫外線(narrow band ultraviolet B:UVB)などの光線治療,③インターフェロン,④多剤併用化学療法などがある.
アフェレシスの根拠
流血中の腫瘍細胞(T細胞)にアポトーシスを起こさせ腫瘍量の減少を図る.またMCH class I分子の発現亢進による,細胞傷害性CD8+T細胞の活性化を図る.extracorporeal photopheresis(ECP)単独では紅皮症型菌状息肉症とSezary症候群のoverall responses(OR)rateはそれぞれ36%,25%,さらに安全寛解が10%で得られるとされている.
1) Schwarz J, Winter JL, Padmanabhan A, et al:Guidlines on the use of therapeutic apheresis in clinicalpractice-evidence-based approch from the Writing Committee of the American Society for Apheresis:the sixth special issue. J Clin Apher 2013;28:145-284 2) McKenna KE, Whittaker S, Rhodes LE, et al:Evidence-based practice of photopheresis 1987-2001:a report of a workshop of the British Photodermatology Group and the UK. Skin lymphoma Group. Br J Dermatol 2006;154:7-20 3) Scarisbirk JJ, Taylor P, Holtick U, et al:U.K. consensus statement on the use of extracorporeal phtopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease. Br J Dermatol 2008;158:659-78 4) Child FJ, Mitchell TJ, Whittaker SJ, et al:A randomized cross-over study to compare PUVA And extracorporeal photophereis in the treatment of plaque stage (T2) mycosis fungoides. Clin Exp Dermatol 2004;29:231-6 5) Knobler R, Duvic M, Querfeld C, et al:Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis. Photodermatol Photoimmunol Photomed 2012;28:250-7 6) Szczepiorkowski ZM, Burnett CA, Dumont LJ, et al:Apheresis buffy coat collection without photoactivation has no effect on apotosis, cell proliferation, and total viability of mononuclear cells collected using photopheresis systems. Transfusion 2018;58:947-50 7) Dippel E, Schrag H, Goerdt S, et al:Extracorporeal photopheresis and interferon-alpha in advanced cutaneous T-cell lymphoma. Lancet 1997;350:32-3 8) Zouboulis CC, Schmuth M, Doepfmer S, et al:Extracorporeal photopheresis of cutaneous T-cell lymphoma is associated with reduction of peripheral CD4+T lymphocytes. Dermatology 1998;196:305-8 9) Demierre MF, Ferzli P, Miller D, et al:Measuring HRQOL in patients with cutaneous T-cell lymphoma undergoing therapy with oral bexarotene and extracorporeal photopheresis. Arch Dermatol 2007;143:659-61 10) Booken N, Weiss C, Utikal J, et al:Combination therapy with extracorporeal photopheresis, interferon-alpha, PUVA and topical corticosteroids in the management of Sezary syndrome. J Dtsch Dermatol Ges 2010;8:428-38 11) Talpur R, Demierre MF, Geskin L, et al:Multicenter photopheresis intervention trail in early-stage mycosis fungoides. Clin Lymphoma Myeloma Leuk 2011;11:219-27